The number of lung cancer cases in people who have never smoked is increasing. The disease is different from lung cancer ...

Patients with stage II and IIIB non-small cell lung cancer (NSCLC) with an EGFR mutation had better outcomes when treated ...

Dr. Suresh Ramalingam discusses how Tagrisso has ushered in a new era of care for patients with advanced EGFR+ non-small cell ...

Oncologists share their treatment preferences for patients with advanced NSCLC with EGFR mutations. Improving survival and ...

EGFR inhibitors such as Erbitux and Gilotrif show potential in laboratory and mouse studies in treating melanoma with a ...

SMMT's HARMONi trial shows PFS benefits for ivonescimab in EGFR-mutant NSCLC, but lack of proven overall survival raises ...

ASCO Data Shows New Therapy Extends Survival in Small Cell Lung Cancer. Here's what you need to know about the new ...

Jill Feldman discusses the background of the phase 2 COCOON trial in advanced non–small cell lung cancer with EGFR mutations.

In its first global phase 3 readout, Akeso and Summit Therapeutics’ closely watched PD-1xVEGF bispecific antibody ivonescimab ...

The MHRA has approved aumolertinib for adult patients with non-small cell lung cancer (NSCLC), following a groundbreaking ...